Another risky one but with a new income stream things are looking up for Sun.
Why they did not perform better last year is anyones guess.
I suppose the big boys have been let down before but this time its different .
Take a look - long term holder.....

Surgical Innovations Group plc
("SI" or "the Group")
FDA Approval for Logi Flex

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of
innovative medical devices, is pleased to announce that it is has received
510(k) clearance from the US Food and Drug Administration ("FDA") for its Logi
Flex device.
This clearance permits the use of Logi Flex in the US market for both gastric
band deployment and other associated bariatric procedures.
Logi Flex is a Resposable articulating instrument which combines both reusable
and disposable elements - the insert is single use and the handle is reusable -
to offer surgeons a high quality and cost effective solution.
The device has a sterile insert which allows surgeons to fix gastric bands
around the top of a patient's stomach. It also has a unique slot design which
provides a positive grip on the suture allowing the band to be pulled into
position with the minimum of inconvenience.
It is estimated that 250,000 anti-obesity procedures are performed annually in
the US where obesity affects more than 60 million people, representing the
second largest cause of preventable death.
Graham Bowland, Chief Executive Officer of the Group, said: "We are delighted to
be able to announce this approval which will see the pioneering device now being
sold into the US. The majority of surgical instruments in the US are single
use; however with growing financial constraints being placed on hospital
budgets, procurement managers are continuously looking for cost effective
instrumentation and Logi Flex offers the ideal high quality, cost effective
solution."

All this good news will be reflected in the SP sooner or later!!

Results next Tuesday - I'm not too excited!

They should be good !!

Nar 1, on what do you base your comments ?

Pumben, They are always good

great to see some in depth analysis there....

not that i'm going to add anything more constructive than "am crossing fingers"

Interim Results.

Financial highlights

Revenue increased by 79% to 3.57 million (H1 2009: 1.99 million)

Operating profit increased by 234% to 781,000 (H1 2009: 234,000)

Net cash of 888,000 generated from operating activities

Pre-tax profit increased by 256% to 766,000 (H1 2009: 215,000)

Basic earnings per share of 0.18p (H1 2009: 0.05p)

skinny you forgot cancellation of share premium account with a view to be able to pay dividends in the future - lol

Not bad results

Hmmm - looks like 5p bid may be finally - cleared.

Another reasonable move / volume today. I dug out my original buy details from March 2000 @6.75. I might even break even at some point!

You did better than me, Skinny. I paid 7.25p for my first lot on March 23, 2000. But I've been a steady buyer ever since and my average price is 4.25. I've found that these tend to disappoint around results time. Prelims are due in April. Must make a note to keep a close watch.

According to my old spread sheet, I bought on March 21st. On the same spreadsheet are other gems such as :-Atlantic Caspian @10p, Reflec @4p (although sold in the 30s)
Auther Shaw (are you sure) @between 1p and 15p. Ultrasis @45p and ADVFN @30p.

hey ho!

The sun has got his hat on - highest since 2007 wow..... things are looking up.

RNS Number : 4836Z

Surgical Innovations Group PLC

14 January 2011


For immediate release 14 January 2011

Surgical Innovations Group plc

("SI" or "the Group")

Trading update

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, today announces an update on trading for the year ended 31 December 2010.

SI continued to trade well in the second half of 2010 and early indications for the full year are that the Group has performed in line with market expectations.

Graham Bowland, Chief Executive Officer, said: "SI made good progress in 2010 with its Resposable(R) products and OEM business, while continuing to grow its own branded products. The Group benefits from a strong underlying business and we are cautiously optimistic going forward with a number of additional larger OEM prospects in the pipeline for the year ending 31 December 2011. However these contracts can take longer to materialise and are not guaranteed. The board will keep shareholders updated. "

Preliminary results for the year to 31 December 2010 are due to be released on Tuesday 19 April 2011.

- Ends -

Surgical Innovations Group plc

("SI" or "the Group")

Appointments to the Clinical Advisory Board

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, is pleased to announce the appointment of arthroscopic specialist Mr Jon Conroy and laparoscopic specialist Mr Marco Adamo to its Clinical Advisory Board (CAB) with immediate effect.

Mr Jon Conroy, BSc, MB ChB, FRCS (Eng), FRCS (Tr & Orth), MSc, is a Consultant Orthopaedic Surgeon specialising in joint replacements and arthropscopic, or 'keyhole', surgeries to the hip and knee. Mr Conroy is a member of the British Hip Society, International Society of Hip Arthroscopy, The British Orthopaedic Association and a Fellow of The Royal College of Surgeons of England. He also holds a master's degree in Mechanical Engineering from Leeds University. Mr Conroy has published research in several medical journals and won the GlaxoSmithKlein Orthopaedic Essay Prize in 2005 and the John Fitton Prize for Orthopaedic Specialist Registrars in 2006.

Mr Marco Adamo, MD is a Consultant Surgeon and Bariatric Surgery Lead at the University College London Hospital (UCLH) where he has worked since 2007. He graduated in 1995 with full marks and honours in Palermo, Italy where he also completed his training in general surgery. Since moving to the UK in 2000 he has focused on advanced laparoscopic surgery and laparoscopic bariatric (obesity) surgery. He performed the first single incision laparoscopic sleeve gastrectomy in the UK and also has a specific interest in laparoscopic hernia surgery. As a dedicated trainer in his field he often runs advanced training courses for UK and European surgeons. Mr Adamo is a member of the European Association of Endoscopic Surgery (EAES), British Society for Metabolic and Obesity Surgery (BOMSS), Association of Upper-GI Surgeons (AUGIS) and Association of Laparoscopic Surgeons in UK (ALS) and Italy (SICE).

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "We are very pleased to welcome Jon and Marco to the CAB. Jon's expertise in arthroscopy will be invaluable as we begin to develop minimally invasive surgical devices for this very important market. Marco's appointment will strengthen our specialist bariatric team and significantly add value to the development of devices for this particular area of surgery. Our CAB now consists of nine highly experienced surgeons covering a wide range of specialism and markets."

SUN having another run on reasonable volume.

Up on reasonable volume (for SUN).

Final Results

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, is pleased to announce its final results for the 12 months ending 31 December 2010.

Financial highlights

-- Revenue increased 55% to GBP7.045 million (2009: GBP4.541 million)

-- Pre-tax profit increased 487% to GBP1.549 million (2009: GBP264,000)

-- Operating margins increased to 22% (2009: 6%)

-- Net cash of GBP2.2 million generated from operating activities

-- Basic earnings per share of 0.48p (2009: 0.14p)

Operational highlights

-- Own brand sales increased 30% to GBP3.852 million (2009: GBP2.956 million); driven by flagship Resposable(R) products

-- OEM revenues increased 71% to GBP2.506 million (2009: GBP1.463 million)

-- Industrial sales boosted by delivery of GBP616,000 order

-- Continued major investment in research and development, plant and manufacturing

Doug Liversidge, Chairman of the Group, said: "The Group has undergone yet another year of transformation, successfully meeting the demands of rapid growth. We have continued to invest heavily in the business while R&D capability has undergone a step-change to speed up new product development and improvements to our existing technology. This has proven to be very appealing to potential OEM customers and as a result we are seeing an influx of enquires for a range of minimally invasive devices. With an already promising start to 2011, we are looking forward with confidence."